Top Markets
#1 Akedo Akedo +73.50%
#2 MEET48 MEET48 +26.11%
#3 Bitway Bitway +21.76%
#4 VeThor VeThor +21.08%
#5 Power Protocol Power Protocol +17.38%
#6 Tutorial Tutorial +16.23%
#7 Astar Astar +14.86%
#8 龙虾 (Lobster) 龙虾 (Lobster) +12.72%
#9 Falcon Finance Falcon Finance +12.11%
#10 Arbitrum Arbitrum +12.09%
Coin of the day
Akedo Akedo
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Kedudukan dalam Saham #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Harga Saham
$0.25974701
Disegerakkan terakhir: 2025-01-06
Modal Pasaran
$2.04M
Perubahan (1 hari)
0.74%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan Acticor Biotech SAS (ALACT)

Kategori

Healthcare
Pendapatan untuk Acticor Biotech SAS (ALACT)
Pendapatan pada Jun 2024 TTM: $-12.93M
Menurut laporan kewangan terkini Acticor Biotech SAS, pendapatan semasa syarikat ialah $-12.93M. Pada tahun 2022, syarikat memperoleh pendapatan sebanyak $-19.33M, penurunan berbanding pendapatan pada tahun 2021 yang berjumlah $-16.54M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Acticor Biotech SAS dari 2010 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-12.93M -43.60%
2023 $-22.92M 18.60%
2022 $-19.33M 16.85%
2021 $-16.54M 50.20%
2020 $-11.01M 86.82%
2019 $-5.89M -14.36%
2018 $-6.88M -41.98%
2017 $-11.86M 2,061.40%
2016 $-548.85K -76.37%
2015 $-2.32M 97.57%
2014 $-1.18M -131.38%
2013 $3.75M -11.81%
2012 $4.25M 30.59%
2011 $3.25M 275.68%
2010 $865.72K 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -40,906.21%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -15,190.08%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 30,968.98%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 23,780.79%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH